174 related articles for article (PubMed ID: 11911255)
21. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.
Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
Anticancer Res; 1992; 12(4):1147-53. PubMed ID: 1386970
[TBL] [Abstract][Full Text] [Related]
23. Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism.
Lewis KC; Zech LA; Phang JM
Cancer Res; 1994 Aug; 54(15):4112-7. PubMed ID: 8033144
[TBL] [Abstract][Full Text] [Related]
24. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Takahashi N; Sausville EA; Breitman TR
Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
[TBL] [Abstract][Full Text] [Related]
25. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
26. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
28. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
29. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Sugamata N; Koibuchi Y; Iino Y; Morishita Y
Int J Oncol; 1999 Feb; 14(2):259-63. PubMed ID: 9917500
[TBL] [Abstract][Full Text] [Related]
30. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
31. [Anti-carcinogenic and anti-blastic effect of vitamin A in various modes of its administration to random-bred rats during carcinogenesis of the mammary gland, induced by 7,12-dimethylbenz(a)anthracene].
Piatchanina TV; Kartavova NS; Gutnik NS; Sidorik EP
Eksp Onkol; 1989; 11(5):20-3. PubMed ID: 2507271
[TBL] [Abstract][Full Text] [Related]
32. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
Takahashi N; Watanabe Y; Maitani Y; Yamauchi T; Higashiyama K; Ohba T
Int J Cancer; 2008 Feb; 122(3):689-98. PubMed ID: 17955489
[TBL] [Abstract][Full Text] [Related]
33. Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumor induction in mice.
McCormick DL; Bagg BJ; Hultin TA
Cancer Res; 1987 Nov; 47(22):5989-93. PubMed ID: 2959358
[TBL] [Abstract][Full Text] [Related]
34. N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver.
Matsuura T; Zhao Z; Ross AC
J Nutr; 1996 Oct; 126(10):2474-80. PubMed ID: 8857507
[TBL] [Abstract][Full Text] [Related]
35. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
36. Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells.
Bunk MJ; Kinahan JJ; Sarkar NH
Cancer Lett; 1985 Apr; 26(3):319-26. PubMed ID: 2986832
[TBL] [Abstract][Full Text] [Related]
37. Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye.
Lewis KC; Zech LA; Phang JM
Eur J Cancer; 1996 Sep; 32A(10):1803-8. PubMed ID: 8983293
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
[TBL] [Abstract][Full Text] [Related]
39. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
[TBL] [Abstract][Full Text] [Related]
40. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
